Literature DB >> 1900070

Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss.

M D Creagh1, R G Malia, S M Cooper, A R Smith, S L Duncan, M Greaves.   

Abstract

Sixty six women with first or second trimester fetal loss were investigated for the presence of lupus anticoagulant by routine coagulation tests and the dilute Russell's viper venom time with a platelet neutralisation procedure, and for raised anticardiolipin antibodies by an enzyme linked immunosorbent assay. Of 35 women with recurrent fetal loss, seven were positive for lupus anticoagulant and six had increased IgG anticardiolipin antibodies, while of 31 women with only one or two episodes of fetal loss, one had lupus anticoagulant and none increased IgG anticardiolipin antibodies. These findings were significantly different. There was no difference in the incidence of increased IgM anticardiolipin antibodies between the two groups (three and two cases, respectively). A further 11 women with intrauterine death in the third trimester were studied and lupus anticoagulant and raised IgM anticardiolipin antibodies were found in one case. No woman was known to have systemic lupus erythematosus. It is concluded that lupus anticoagulant and increased IgG anticardiolipin antibodies are independently associated with recurrent first and second trimester fetal loss and that such cases should be investigated, even in the presence of otherwise good health, by a comprehensive methodological approach.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900070      PMCID: PMC497013          DOI: 10.1136/jcp.44.1.45

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

Review 1.  Pregnancy and antibodies to phospholipids.

Authors:  M J Walport
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.

Authors:  P Thiagarajan; V Pengo; S S Shapiro
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

3.  Clinical manifestations and laboratory findings in patients with lupus anticoagulants.

Authors:  A Kornberg; L Silber; R Yona; S Kaufman
Journal:  Eur J Haematol       Date:  1989-01       Impact factor: 2.997

4.  Lupus anticoagulant in women with multiple spontaneous miscarriage.

Authors:  M A Howard; B G Firkin; D L Healy; S C Choong
Journal:  Am J Hematol       Date:  1987-10       Impact factor: 10.047

5.  Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women.

Authors:  M Petri; M Golbus; R Anderson; Q Whiting-O'Keefe; L Corash; D Hellmann
Journal:  Arthritis Rheum       Date:  1987-06

6.  Intrauterine death and circulating anticoagulant ("antithromboplastin").

Authors:  I M Nilsson; B Astedt; U Hedner; D Berezin
Journal:  Acta Med Scand       Date:  1975-03

7.  Screening for postmenopausal osteoporosis.

Authors:  M R Davis
Journal:  Am J Obstet Gynecol       Date:  1987-01       Impact factor: 8.661

8.  Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test.

Authors:  E N Harris; J K Chan; R A Asherson; V R Aber; A E Gharavi; G R Hughes
Journal:  Arch Intern Med       Date:  1986-11

9.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

10.  Antibodies to phospholipids and nuclear antigens in patients with repeated abortions.

Authors:  S Cowchock; J B Smith; B Gocial
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

  10 in total
  1 in total

1.  Recurrent fetal loss and antiphospholipid antibodies: clinical and therapeutic aspects.

Authors:  O Blétry; A M Piette
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.